Click here to close now.

Welcome!

News Feed Item

Horizon Pharma Reports Second Quarter 2014 Financial Results and Provides Business Update

Record Second Quarter Net Revenue of $66.1 Million

DEERFIELD, IL -- (Marketwired) -- 08/07/14 -- Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the second quarter ended June 30, 2014.

Quarterly Financial Highlights

  • Total net sales of $66.1 million versus $11.1 million in second quarter of 2013
  • Adjusted EBITDA of $23.8 million
  • Adjusted non-GAAP net income of $20.7 million, or $0.21 non-GAAP diluted earnings per share
  • Cash and cash equivalents of $128.9 million at June 30, 2014

"We saw continued strong revenue and adjusted EBITDA growth in the second quarter, including quarter over quarter sequential net sales growth of 27% and adjusted EBITDA growth of 97%," said Timothy P. Walbert, chairman, president and chief executive officer. "VIMOVO, DUEXIS and RAYOS each grew double digits in prescriptions and net sales. As a result, we are confident in reiterating our prior net sales guidance range for fiscal 2014 of $270 to $280 million and our adjusted EBITDA range of $80 to $90 million, with expectation of September close of the Vidara acquisition. In addition, we believe we have developed strategies which can allow us to mitigate the effect of the impact of being placed on the Express Scripts and CVS/Caremark exclusion lists in 2015. This, along with a full year of ACTIMMUNE sales, allows us to provide preliminary net sales guidance for 2015 in the range of $380 million to $405 million and preliminary adjusted EBITDA guidance of $150 million to $170 million."

Second Quarter 2014 Financial Results

  • Total net sales in the second quarter of 2014 were a record $66.1 million, compared with $11.1 million in the second quarter of 2013, representing 495% year over year growth. Quarter over quarter sequential net sales growth was approximately 27% compared with the first quarter of 2014. Consistent with industry practice, as of this quarter the Company will no longer report gross sales or gross-to-net discounts and will be reporting only net sales.
  • Total net sales of VIMOVO®, DUEXIS® and RAYOS® in the second quarter of 2014 were $42.4 million, $17.8 million and $3.9 million, respectively.
  • Gross profit margins were 62% of net sales in the second quarter of 2014 compared with 78% of net sales in the second quarter of 2013, and were 94% of net sales in the second quarter of 2014 and 2013 after excluding depreciation, intangible amortization, expenses associated with a change in estimate of VIMOVO royalty liability and accretion of VIMOVO royalties.
  • Total operating expenses were $48.4 million in the second quarter of 2014, compared to $24.5 million in the second quarter of 2013 and $42.7 million in the first quarter of 2014. Second quarter 2014 operating expenses included $5.8 million related to the Vidara transaction.
  • On a GAAP basis, net loss in the second quarter of 2014 was $27.8 million, or $0.38 per share, which includes Vidara acquisition related operating expenses of $5.8 million and $4.3 million in Vidara commitment fee amortization for total Vidara related expenses of $10.1 million, a change in estimate of VIMOVO royalty liability of $13.0 million and a non-cash charge of $11.0 million related to the increase in fair value of the embedded derivative associated with the Company's convertible senior notes due primarily to an increase in volatility and the market value of the Company's common stock during the second quarter. As of June 30, 2014, with the recent approval by the Company's stockholders of shares that would be required to convert the convertible senior notes into common stock, the convertible notes are no longer required to be settled in cash and therefore, the total liability of $324.4 million has been reclassified into equity and there will be no further adjustment of the derivative liability in future periods.
  • Adjusted non-GAAP net income was $20.7 million, or $0.28 adjusted non-GAAP basic earnings per share and $0.21 adjusted non-GAAP diluted earnings per share.
  • Adjusted EBITDA was $23.8 million after excluding the impact of $10.1 million in Vidara acquisition related expenses, $13.0 million for a change in estimate of VIMOVO royalty liability, $11.0 million related to the increase in fair value of the embedded derivative associated with the Company's convertible senior notes and other non-GAAP adjustments.
  • The Company had cash and cash equivalents of $128.9 million as of June 30, 2014, an increase of $25.5 million from March 31, 2014. During the second quarter of 2014, the Company generated $16.8 million in cash from operating activities or, after excluding payments made in connection with Vidara acquisition expenses, $20.1 million in adjusted non-GAAP cash from operating activities.

First Half 2014 Financial Results

  • Total net sales in the first six months of 2014 were $118.0 million, compared with $19.8 million in the first six months of 2013, representing 495% year over year growth.
  • Total net sales of VIMOVO®, DUEXIS® and RAYOS® in the first six months of 2014 were $76.4 million, $31.7 million and $7.2 million, respectively.
  • Gross profit margins were 73% of net sales in the first six months of 2014 compared with 69% of net sales in the first six months of 2013, and were 95% of net sales in the first six months of 2014, excluding depreciation, intangible amortization, expenses associated with a change in estimate of VIMOVO royalty liability and accretion of VIMOVO royalties, compared to 86% of net sales in the first six months of 2013 on the same basis.
  • Total operating expenses were $91.1 million in the first six months of 2014, compared to $48.0 million in the first six months of 2013.
  • On a GAAP basis, net loss in the first six months of 2014 was $234.0 million, or $3.34 per share, which includes a non-cash charge of $215.0 million related to the increase in fair value of the embedded derivative associated with the Company's convertible senior notes due primarily to an increase in the market value of the Company's common stock during the first half of 2014, $14.2 million of Vidara acquisition related expenses and a change in estimate of VIMOVO royalty liability of $13.0 million.
  • Adjusted non-GAAP net income in the first six months of 2014 was $31.7 million, or $0.45 adjusted non-GAAP basic earnings per share and $0.34 adjusted non-GAAP diluted earnings per share.
  • Adjusted EBITDA in the first six months of 2014 was $35.9 million after excluding the impact of $14.2 million in Vidara acquisition related expenses, $13.0 million for a change in estimate of VIMOVO royalty liability, $215.0 million related to the increase in fair value of the embedded derivative associated with the Company's convertible senior notes and other non-GAAP adjustments.
  • During the first six months of 2014, the Company generated $16.0 million of cash from operating activities, or after excluding payments made in connection with the Vidara acquisition, $24.5 million in adjusted non-GAAP cash from operating activities.

2015 Guidance

Today the Company provided preliminary net revenue guidance for 2015 in the range of $380 million to $405 million and preliminary adjusted EBITDA guidance in the range of $150 million to $170 million, with expectation of September close of the Vidara acquisition. We will review expected net revenue and adjusted EBITDA guidance for 2015 and update as appropriate in the fourth quarter of this year.

Business Update

  • Announced execution of $300 million senior secured credit agreement and early termination of Hart-Scott-Rodino waiting period in connection with the proposed acquisition of Vidara.
  • Announced transition plan and named Paul Hoelscher Executive Vice President and Chief Financial Officer following retirement of Robert De Vaere in September.
  • Appointed H. Thomas Watkins to the Company's board of directors.
  • Announced additional Notice of Allowance by the U.S. Patent and Trademark Office with claims covering RAYOS.
  • Announced two Notices of Allowance by the U.S. Patent and Trademark Office with claims covering VIMOVO.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain financial measures such as adjusted non-GAAP net income (loss), adjusted non-GAAP net income (loss) per share, non-GAAP gross profit margins and non-GAAP cash from operations, that include adjustments to GAAP figures. These adjustments to GAAP exclude acquisition transaction related expenses as well as non-cash items such as stock compensation, depreciation and amortization, accretion, non-cash interest expense, and other non-cash adjustments such as the increase or decrease in the fair value of the embedded derivative associated with the Company's convertible senior notes. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are also used and provided by Horizon as non-GAAP financial measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company's operational results and trends. In addition, these non-GAAP financial measures are among the indicators Horizon's management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the financial statements portion of this press release where the Company has provided a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. However, the Company has not provided a reconciliation of full year 2014 adjusted EBITDA outlook to a net income (loss) outlook because certain items that are a component of net income (loss) but not part of adjusted EBITDA, such as the gain (loss) on derivative revaluation associated with the convertible senior notes, stock compensation and acquisition related expenses, cannot be reasonably projected, either due to the significant impact of changes in Horizon's stock price on derivative revaluation and stock compensation, or the variability associated with acquisition related expenses due to timing and other factors.

Conference Call

At 8:00 a.m. Eastern Time today, Horizon's management will host a live conference call and webcast to review the Company's financial and operating results and provide a general business update.

The live webcast and a replay may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

Alternatively, please call 1-888-338-8373 (U.S.) or 973-872-3000 (international) to listen to the conference call. The conference ID number for the live call is 80185634. Telephone replay will be available approximately two hours after the call. To access the replay, please call 1-855-859-2056 (U.S.) or 404-537-3406 (international). The conference ID number for the replay is 80185634.

About Horizon Pharma

Horizon Pharma, Inc. (NASDAQ: HZNP) is a specialty pharmaceutical company focused on improving patients' lives by identifying, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in the areas of arthritis, pain and inflammatory diseases. The company's U.S. marketed products are VIMOVO® (naproxen/esomeprazole), DUEXIS® (ibuprofen/famotidine) and RAYOS® (prednisone) delayed-release tablets. The company has announced the acquisition of Vidara Therapeutics International Public Limited Company ("Vidara") through a reverse merger, which is expected to close in September. Upon the closing of the Vidara transaction, the company will add ACTIMMUNE® (interferon gamma-1b), an orphan product marketed for use in children and adults with chronic granulomatous disease and severe, malignant osteopetrosis, to its portfolio of U.S. marketed products. For more information, please visit www.horizonpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding expected 2014 and 2015 net revenue and adjusted EBITDA, the expected timing for closing of the Vidara acquisition and the on-going commercialization of DUEXIS, VIMOVO and RAYOS and future commercialization of ACTIMMUNE. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, risks regarding Horizon's ability to commercialize products successfully, including risks relating to availability of coverage and adequate reimbursement and pricing from government and third party payers and risks relating to the success of our Prescriptions-Made-Easy or PME specialty pharmacy program, whether commercial data regarding DUEXIS, VIMOVO, RAYOS and ACTIMMUNE in the United States for any historic periods are indicative of future results, Horizon's ability to comply with post-approval regulatory requirements, Horizon's ability to enforce its intellectual property rights to its products, whether and when Horizon will be able to satisfy the conditions precedent to close its proposed merger with Vidara, Horizon's ability to execute on its plan to grow through acquisition of or in-licensing additional products or companies where it can execute a targeted commercial approach among specific target physicians and whether any such acquisitions or in-licensing transactions will leverage the Company's commercial strengths and infrastructure. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update or revise these statements, except as may be required by law.

Additional Information and Where to Find It

In connection with the proposed transaction, Horizon and Vidara have filed documents with the SEC, including the filing by Horizon of a preliminary proxy statement/prospectus relating to the proposed transaction and the filing by Vidara of a registration statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the registration statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to Horizon stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT HORIZON, VIDARA AND THE PROPOSED TRANSACTION. Investors and security holders may obtain free copies of these documents (when they are available) and other related documents filed with the SEC at the SEC's web site at www.sec.gov, by directing a request to Horizon's Investor Relations department at Horizon Pharma, Inc., Attention: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015 or to Horizon's Investor Relations department at 224-383-3000 or by email to [email protected]. Investors and security holders may obtain free copies of the documents filed with the SEC on Horizon's website at www.horizonpharma.com under the heading "Investors" and then under the heading "SEC Filings."

Horizon and its directors and executive officers and Vidara and its directors and executive officers may be deemed participants in the solicitation of proxies from the stockholders of Horizon in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed transaction will be included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of Horizon is also included in Horizon's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the SEC on March 13, 2014. These documents are available free of charge at the SEC's web site at www.sec.gov and from Investor Relations at Horizon as described above.

This communication does not constitute an offer to sell, or the solicitation of an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


                   CONDENSED CONSOLIDATED BALANCE SHEETS
              (in thousands, except share and per share data)

                                                            As of
                                                 --------------------------
                                                   June 30,    December 31,
                                                     2014          2013
                                                 ------------  ------------
Assets                                                           (Unaudited)
Current assets
  Cash and cash equivalents                      $    128,851  $     80,480
  Restricted cash                                         738           738
  Accounts receivable, net                             51,792        15,958
  Inventories, net                                      9,203         8,701
  Prepaid expenses and other current assets             7,091         4,888
                                                 ------------  ------------
      Total current assets                            197,675       110,765
  Property and equipment, net                           4,031         3,780
  Intangible assets, net                              120,497       131,094
  Other assets                                          6,161         6,957
                                                 ------------  ------------
      Total assets                               $    328,364  $    252,596
                                                 ============  ============
Liabilities and Stockholders' Equity
 Current liabilities
  Convertible debt, net                          $    114,786  $          -
  Accounts payable                                     15,896         9,921
  Accrued trade discounts and rebates                  37,584         8,123
  Accrued expenses                                     19,236        15,926
  Accrued royalties - current portion                  14,869         8,010
  Deferred revenues - current portion                   2,000         1,330
                                                 ------------  ------------
      Total current liabilities                       204,371        43,310
 Long-term liabilities
  Convertible debt, net of current                          -       110,762
  Derivative liability                                      -       109,410
  Accrued royalties, net of current                    30,759        24,982
  Deferred revenues, net of current                     9,297         9,686
  Deferred tax liabilities, net                         3,102         3,362
  Other long term liabilities                             165           166
                                                 ------------  ------------
      Total long-term liabilities                      43,323       258,368
                                                 ------------  ------------

Commitments and contingencies

Stockholders' equity
  Common stock, $0.0001 par value per share;
   200,000,000 shares authorized; 74,285,710 and
   66,097,417 shares issued and outstanding at
   June 30, 2014 and December 31, 2013,
   respectively.                                            8             7
  Additional paid-in capital                          774,339       410,430
  Accumulated other comprehensive loss                 (2,542)       (2,403)
  Accumulated deficit                                (691,135)     (457,116)
                                                 ------------  ------------
      Total stockholders' equity (deficit)             80,670       (49,082)
                                                 ------------  ------------
      Total liabilities and stockholders' equity $    328,364  $    252,596
                                                 ============  ============



              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
              (in thousands, except share and per share data)

                            Three Months Ended         Six Months Ended
                                 June 30,                  June 30,
                         ------------------------  ------------------------
                             2014         2013         2014         2013
                         -----------  -----------  -----------  -----------
                                (Unaudited)               (Unaudited)
Net sales                $    66,062  $    11,131  $   117,988  $    19,824
Cost of goods sold            24,810        2,394       32,429        6,163
                         -----------  -----------  -----------  -----------
  Gross profit                41,252        8,737       85,559       13,661
                         -----------  -----------  -----------  -----------

Operating expenses
  Research and
   development                 3,545        2,833        6,378        5,031
  Sales and marketing         27,126       16,526       55,821       32,854
  General and
   administrative             17,681        5,182       28,873       10,124
                         -----------  -----------  -----------  -----------
    Total operating
     expenses                 48,352       24,541       91,072       48,009
                         -----------  -----------  -----------  -----------
Operating loss                (7,100)     (15,804)      (5,513)     (34,348)

Interest expense, net         (4,207)      (3,442)      (8,414)      (7,045)
Foreign exchange (loss)
 gain                           (284)         454         (322)        (451)
Loss on derivative fair
 value                       (10,965)           -     (214,995)           -
Other expense                 (4,333)           -       (5,000)           -
                         -----------  -----------  -----------  -----------
Loss before expense
 (benefit) for income
 taxes                       (26,889)     (18,792)    (234,244)     (41,844)
Expense (benefit) for
 income taxes                    880         (351)        (225)      (1,232)
                         -----------  -----------  -----------  -----------
Net loss                 $   (27,769) $   (18,441) $  (234,019) $   (40,612)
                         ===========  ===========  ===========  ===========

Net loss per share-
 basic and diluted       $     (0.38) $     (0.29) $     (3.34) $     (0.65)
                         ===========  ===========  ===========  ===========
Weighted average shares
 outstanding used in
 calculating net loss
 per
share - basic and
 diluted                  73,384,801   62,872,173   70,164,267   62,339,285
                         -----------  -----------  -----------  -----------



       RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET INCOME (LOSS)
             (in thousands, except share and per share amounts)

                            Three Months Ended         Six Months Ended
                                 June 30,                  June 30,
                         ------------------------  ------------------------
                             2014         2013         2014         2013
                         -----------  -----------  -----------  -----------
                                (Unaudited)               (Unaudited)
Adjusted Non-GAAP Net
 Income (Loss):

  GAAP Net Loss          $   (27,769) $   (18,441) $  (234,019) $   (40,612)
  Non-GAAP Adjustments:
    Change in estimate
     of VIMOVO royalties      13,033            -       13,033            -
    Loss on derivative
     revaluation              10,965            -      214,995            -
    Vidara acquisition
     costs                    10,125            -       14,174            -
    Amortization and
     accretion:
      Intangible
       amortization
       expense (net of
       tax effect)             4,683        1,311        9,363        2,635
      Amortization of
       debt discount and
       deferred
       financing costs         2,333          919        4,666        1,829
      Accretion of
       royalty liability       2,953            -        2,953            -
      Amortization of
       deferred revenue         (161)        (147)        (322)        (215)
    Stock-based
     compensation              4,160        1,021        6,087        2,100
    Depreciation expense         404          299          780          558
                         -----------  -----------  -----------  -----------
      Total of non-GAAP
       adjustments            48,495        3,403      265,729        6,907
                         -----------  -----------  -----------  -----------
  Adjusted Non-GAAP Net
   Income (Loss)         $    20,726  $   (15,038) $    31,710  $   (33,705)
                         ===========  ===========  ===========  ===========

Adjusted Non-GAAP
 Earnings (Loss) Per
 Share:

  Weighted average
   shares - basic         73,384,801   62,872,173   70,164,267   62,339,285
                         ===========  ===========  ===========  ===========

  Weighted average
   shares - diluted
    Weighted average
     shares - basic       73,384,801   62,872,173   70,164,267   62,339,285
    Common stock
     equivalents          24,689,011            -   22,955,502            -
                         -----------  -----------  -----------  -----------
    Weighted average
     shares - diluted     98,073,812   62,872,173   93,119,769   62,339,285
                         ===========  ===========  ===========  ===========


  Adjusted Non-GAAP
   Basic Earnings (Loss)
   Per Share:
    GAAP net loss per
     common share-basic
     and diluted         $     (0.38) $     (0.29) $     (3.34) $     (0.65)
    Non-GAAP adjustments        0.66         0.05         3.79         0.11
                         -----------  -----------  -----------  -----------
    Adjusted Non-GAAP
     Basic Earnings
     (Loss) per share    $      0.28  $     (0.24) $      0.45  $     (0.54)
                         ===========  ===========  ===========  ===========

  Adjusted Non-GAAP
   Diluted Net Income
   (Loss) Per Share:
    Adjusted Non-GAAP
     net income (loss)
     per common share-
     basic               $      0.28  $     (0.24) $      0.45  $     (0.54)
    Dilutive earnings
     per share effect of
     common stock
     equivalents               (0.07)           -        (0.11)           -
                         -----------  -----------  -----------  -----------
    Adjusted Non-GAAP
     net income (loss)
     per common share-
     diluted             $      0.21  $     (0.24) $      0.34  $     (0.54)
                         ===========  ===========  ===========  ===========



                ADDITIONAL GAAP TO NON-GAAP RECONCILIATIONS
                     (in thousands, except percentages)

                            Three Months Ended         Six Months Ended
                                 June 30,                  June 30,
                         ------------------------  ------------------------
                             2014         2013         2014         2013
                         -----------  -----------  -----------  -----------
                                (Unaudited)               (Unaudited)

EBITDA and Adjusted
 EBITDA:

  GAAP Net Loss          $   (27,769) $   (18,441) $  (234,019) $   (40,612)
  Depreciation                   404          299          780          558
  Amortization and
   accretion:
    Intangible
     amortization
     expense                   5,029        1,634       10,056        3,297
    Accretion of royalty
     liability                 2,953            -        2,953            -
    Amortization of
     deferred revenue           (161)        (147)        (322)        (215)
  Interest expense, net
   (including
   amortization of debt
   discount and deferred
   financing costs)            4,207        3,442        8,414        7,045
  Expense (benefit) for
   income taxes                  880         (351)        (225)      (1,232)
                         -----------  -----------  -----------  -----------
  EBITDA                 $   (14,457) $   (13,564) $  (212,363) $   (31,159)
                         -----------  -----------  -----------  -----------
  Non-GAAP adjustments:
    Change in estimate
     of VIMOVO reyalties      13,033            -       13,033            -
    Loss on derivative
     revaluation              10,965            -      214,995            -
    Vidara acquisition
     costs                    10,125            -       14,174            -
    Stock-based
     compensation              4,160        1,021        6,087        2,100
                         -----------  -----------  -----------  -----------
  Total of Non-GAAP
   adjustments           $    38,283  $     1,021  $   248,289  $     2,100
                         -----------  -----------  -----------  -----------
  Adjusted EBITDA        $    23,826  $   (12,543) $    35,926  $   (29,059)
                         ===========  ===========  ===========  ===========

Non-GAAP Gross Profit:
  GAAP net sales         $    66,062  $    11,131  $   117,988  $    19,824
  GAAP cost of goods
   sold                      (24,810)      (2,394)     (32,429)      (6,163)
                         -----------  -----------  -----------  -----------
  GAAP gross profit      $    41,252  $     8,737  $    85,559  $    13,661
                         ===========  ===========  ===========  ===========

  GAAP gross profit %             62%          78%          73%          69%

  Non-GAAP Gross Profit:
    GAAP gross profit    $    41,252  $     8,737  $    85,559  $    13,661
    Non-GAAP gross
     profit adjustments:
      Change in estimate
       of VIMOVO
       royalties              13,033            -       13,033            -
      Intangible
       amortization
       expense                 5,029        1,634       10,056        3,297
      Accretion of
       royalty liability       2,953            -        2,953            -
      Depreciation               148          105          180          175
                         -----------  -----------  -----------  -----------
    Total of Non-GAAP
     adjustments         $    21,163  $     1,739  $    26,222  $     3,472
                         -----------  -----------  -----------  -----------
    Non-GAAP gross
     profit              $    62,415  $    10,476  $   111,781  $    17,133
                         ===========  ===========  ===========  ===========

    Non-GAAP gross
     profit %                     94%          94%          95%          86%

Non-GAAP Cash Provided
 By (Used) in Operating
 Activities:

  GAAP cash provided by
   (used in) operating
   activities            $    16,761  $   (10,899) $    16,004  $   (33,668)
    Cash payments
     related to Vidara
     acquistion                3,369            -        8,464            -
                         -----------  -----------  -----------  -----------
  Non-GAAP cash provided
   by (used in)
   operating activities  $    20,130  $   (10,899) $    24,468  $   (33,668)
                         -----------  -----------  -----------  -----------



              CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                               (in thousands)

                                                  Six Months Ended June 30,
                                                 --------------------------
                                                     2014          2013
                                                 ------------  ------------
Cash flows from operating activities                     (Unaudited)
Net loss                                         $   (234,019) $    (40,612)
Adjustments to reconcile net loss to net cash
 provided by (used in) operating activities
  Change in estimate of VIMOVO royalties               13,033             -
  Depreciation and intangible amortization
   expense                                             10,836         3,855
  Stock-based compensation                              6,087         2,100
  Royalty accretion                                     2,953             -
  Loss on derivative revaluation                      214,995             -
  Amortization of debt discount and deferred
   financing costs                                      4,666         1,829
  Paid in kind interest expense                             -         1,525
  Foreign exchange loss                                   322           451
  Changes in operating assets and liabilities:
    Accounts receivable                               (35,835)       (3,880)
    Inventories                                          (510)         (559)
    Prepaid expenses and other current assets          (2,211)          (58)
    Accounts payable                                    5,980          (348)
    Accrued trade discounts and rebates                29,469         4,181
    Accrued expenses                                      (27)         (386)
    Deferred revenues                                     362          (774)
    Deferred tax liabilities                             (232)       (1,203)
    Other non-current assets and liabilities              135           211
                                                 ------------  ------------
      Net cash provided by (used in) operating
       activities                                      16,004       (33,668)
                                                 ------------  ------------
Cash flows from investing activities
Purchase of property and equipment                     (1,037)         (345)
                                                 ------------  ------------
      Net cash used in investing activities            (1,037)         (345)
                                                 ------------  ------------
Cash flows from financing activities
Proceeds from the issuance of common stock in
 connection with warrant and stock option
 exercises                                             32,769             -
Proceeds from the issuance of common stock under
 an ATM agreement, net of issuance costs                    -         3,039
Proceeds from the issuance of common stock
 through ESPP programs                                    649           204
Repayment of notes payable                                  -        (3,978)
                                                 ------------  ------------
      Net cash provided by (used in )financing
       activities                                      33,418          (735)
                                                 ------------  ------------

                                                 ------------  ------------
Effect of exchange rate changes on cash and cash
 equivalents                                              (14)            1
                                                 ------------  ------------
      Net increase (decrease) in cash and cash
       equivalents                                     48,371       (34,747)
Cash and cash equivalents
Beginning of period                                    80,480       104,087
                                                 ------------  ------------
End of period                                    $    128,851  $     69,340
                                                 ------------  ------------


Contacts:

Robert J. De Vaere
Executive Vice President, Chief Financial Officer
Email Contact

Robert F. Carey
Executive Vice President, Chief Business Officer
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The 17th International Cloud Expo has announced that its Call for Papers is open. 17th International Cloud Expo, to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, APM, APIs, Microservices, Security, Big Data, Internet of Things, DevOps and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding bu...
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development...
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The basic integration architecture, as defined by ESBs, hasn’t changed for more than a decade. Most cloud integration providers still rely on an ESB architecture and their proprietary connectors. As a result, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable across other integration vendors. However, the rapid adoption of APIs and almost ubiquitous availability of APIs amongst most SaaS and Cloud applications are ra...
The 5th International DevOps Summit, co-located with 17th International Cloud Expo – being held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the ...
SYS-CON Events announced today that Secure Infrastructure & Services will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Secure Infrastructure & Services (SIAS) is a managed services provider of cloud computing solutions for the IBM Power Systems market. The company helps mid-market firms built on IBM hardware platforms to deploy new levels of reliable and cost-effective computing and hig...
The most often asked question post-DevOps introduction is: “How do I get started?” There’s plenty of information on why DevOps is valid and important, but many managers still struggle with simple basics for how to initiate a DevOps program in their business. They struggle with issues related to current organizational inertia, the lack of experience on Continuous Integration/Delivery, understanding where DevOps will affect revenue and budget, etc. In their session at DevOps Summit, JP Morgenthal...
"We help to transform an organization and their operations and make them more efficient, more agile, and more nimble to move into the cloud or to move between cloud providers and create an agnostic tool set," noted Jeremy Steinert, DevOps Services Practice Lead at WSM International, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
17th Cloud Expo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Meanwhile, 94% of enterprises ar...
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...